Aggregated price index with volume information
Summary:
- Antibiotic Developers stocks up 2.9% on average while median return up 1.2% in a day
- Antibiotic Developers stocks up 8.0% on average while median return up 11.6% in a week
- Antibiotic Developers stocks up 1.0% on average while median return up -0.1% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $SMMT 24.0%
- 1M losers are : Losers for past month are $SPRO -3.6%
- 1W winners are : Winners for past week are $SMMT 13.7%
- 1W losers are : Losers for past week are $MRK -2.8%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 21.7%, for the past 3 months is 6.9%
In the past month for a 5 days rolling window, the highest corrrelation is 70.2%, the lowest correlation is -25.9%, the latest correlation is 42.8%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 48.0% between SMMT and SPRO
The lowest correlation is 10.9% between MRK and PRTK
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript May 1, 2024 Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06. SMMT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies […]
Explore key takeaways from Summit Therapeutics' Q1 2024 earnings, including robust financial positioning and pivotal clinical advancements.
Q1 2024 Summit Therapeutics Inc Earnings Call
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on April 29, 2024, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 10,833 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics,
MIAMI, May 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
MIAMI, April 24, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens.
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]
In the biotech and pharmaceutical world, FDA approval is the number one needle mover for drug stocks. Why? Because FDA approval for a drug or treatment can bring years or even decades of steady, high-margin revenue. This is why investors who specifically look to target drug stocks are always aware of an upcoming FDA catalyst for that company. FDA approvals are bullish whether the company is a pre-revenue startup or a global pharmaceutical giant. At the same time, FDA rejections can tank a drug s